CDKN2A and cancer: For instance, Smitherman et al. found that the mean of the p16INK4a expression in 60 childhood, adolescent, and young adult cancer survivors (aged 18–29 years) was higher than the mean expression in 29 age-matched individuals without cancer (p-value < 0.01) [53].